AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the effectiveness of AMG 479 against
carcinoid and pancreatic neuroendocrine tumors. AMG 479 is an antibody that is made in the
laboratory. Antibodies are highly specific proteins produced by the body's immune system that
recognize foreign substances in the body. AMG 479 has been used in other research studies and
information from those other research studies suggests that AMG 479 may help to prevent the
growth of some neuroendocrine tumors. The observed antitumor activity of AMG 479, together
with the current limited treatment options available for patients with neuroendocrine tumors,
warrant further investigation of AMG 479 in this patient population.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Amgen Brigham and Women's Hospital H. Lee Moffitt Cancer Center and Research Institute Massachusetts General Hospital